Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: A phase II trial (CTEP 7190/Mel47)

Craig L. Slingluff, Gina R. Petroni, Kerrington R. Molhoek, David L. Brautigan, Kimberly A. Chianese-Bullock, Amber L. Shada, Mark E. Smolkin, Walter C. Olson, Alison Gaucher, Cheryl Murphy Chase, William W. Grosh, Geoffrey R. Weiss, Aubrey G. Wagenseller, Anthony J. Olszanski, Lainie Martin, Sofia M. Shea, Gulsun Erdag, Prahlad Ram, Jeffrey E. Gershenwald, Michael J. Weber

Research output: Contribution to journalArticlepeer-review

26 Scopus citations


Purpose: A CTEP-sponsored phase II trial was conducted to evaluate safety and clinical activity of combination therapy with CCI-779 (temsirolimus) and bevacizumab in patients with advanced melanoma. Experimental Design: Patients with unresectable stage III to IV melanoma were treated intravenously with temsirolimus 25 mgweekly and bevacizumab 10mgevery 2 weeks. Adverse events were recorded using CTCAE v3.0. Tumor response was assessed by Response Evaluation Criteria in Solid Tumors and overall survival was recorded. Correlative studies measured protein kinases and histology of tumor biopsies and immune function in peripheral blood. Results: Seventeen patients were treated. Most patients tolerated treatment well, but 2 had grade 4 lymphopenia and 1 developed reversible grade 2 leukoencephalopathy. Best clinical response was partial response (PR) in 3 patients [17.7%, 90% confidence interval (CI) 5, 0-39.6], stable disease at 8 weeks (SD) in 9 patients, progressive disease (PD) in 4 patients, and not evaluable in 1 patient. Maximal response duration for PR was 35 months. Ten evaluable patients had BRAFWT tumors, among whom 3 had PRs, 5 had SD, and 2 had PD. Correlative studies of tumor biopsies revealed decreased phospho-S6K (d2 and d23 vs. d1, P < 0.001), and decreased mitotic rate (Ki67+) among melanoma cells by d23 (P = 0.007). Effects on immune functions were mixed, with decreased alloreactive T-cell responses and decreased circulating CD4+ FoxP3+ cells. Conclusion: These data provide preliminary evidence for clinical activity of combination therapy with temsirolimus and bevacizumab, which may be greater in patients with BRAFwt melanoma. Mixed effects on immunologic function also support combination with immune therapies.

Original languageEnglish (US)
Pages (from-to)3611-3620
Number of pages10
JournalClinical Cancer Research
Issue number13
StatePublished - Jul 1 2013
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: A phase II trial (CTEP 7190/Mel47)'. Together they form a unique fingerprint.

Cite this